The systemic immune response was also explored; a low dosage of azelnidipine could enhance the secretion of CD8+ T cells in the spleen, while a high dosage of azelnidipine could significantly boost the secretion of IFN-γ in both the spleen and the tumor draining lymph node (Figure 6E,F). The gene discussed is CD8A; the disease is neoplasm.